Nevertheless, we already know the assumptions of the future draft amendment to the Reimbursement Act, which were presented by the Department of Drug Policy and Pharmacy at the Ministry of Health at a meeting with representatives of applicants held on July 15 this year. From the information presented at the time, it appears that another major amendment to the Reimbursement Law is being prepared, and therefore another DNUR. Among the issues to be covered by the amendments to the legislation were listed:
- reimbursement of drugs for rare diseases - the Health Ministry has announced a change in its approach to reimbursement of such products, including the introduction of multi-criteria analysis as an additional criterion for evaluating reimbursement applications for these drugs;
- Withdrawal of the possibility introduced by DNUR to include selected OTC drugs in reimbursement; instead of reimbursing OTC drugs, the Health Ministry proposes a new procedure for reimbursement applications - at the call of the Health Minister;
- changing the rules regarding the mandatory reduction in the price of a reimbursed drug after the expiration of market exclusivity - the Health Minis...
Content locked
To gain access to the complete English section of the Medexpress.pl, kindly reach out to us at [email protected].
